Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL69823

FC(F)(F)c1ccccc1OC1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 4/20 0.51
EPHX2 P34913 1/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SCD O00767 5/20 0.48
HTR1A P08908 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A3 Q01959 1/20 0.48
RBP4 P02753 2/20 0.47
TTR P02766 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83377 0.90 HRH1 (0.57) HRH1SCDHTR1ASLC6A2SLC6A3
Hydrochloric Acid SCHEMBL473008 0.89 HRH1 (0.55) HRH1SCDHTR1ASLC6A2SLC6A3
Trifluoroacetic Acid SCHEMBL69693 0.84 HRH1 (0.51) HRH1HTR1ASLC6A2SLC6A3
SCHEMBL1782071 0.81 HTR1A (0.58) HRH1SCDHTR1ASLC6A2SLC6A3
SCHEMBL2819314 0.81 HTR1A (0.58) HRH1SCDHTR1ASLC6A2SLC6A3
SCHEMBL7888184 0.81 HTR1A (0.58) HRH1SCDHTR1ASLC6A2SLC6A3
Hydrochloric Acid SCHEMBL2947998 0.80 HTR1A (0.57) HRH1SCDHTR1ASLC6A2SLC6A3
Trifluoroacetic Acid SCHEMBL5318468 0.77 GPR6 (0.50) HRH1HTR1ASLC6A2SLC6A3
SCHEMBL3132020 0.77 EPHX2 (0.65) EPHX2KDM4ELMNAMAPTNPSR1
SCHEMBL31071563 0.76 SLC6A2 (0.48) HRH1HTR1ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 HRH1 3572/4885EPHX2 1023/4885KDM4E 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.